Immune Checkpoint & Cell Surface Proteins
High-purity recombinant checkpoint proteins and tumor-associated antigens designed for advanced immunotherapy research. Ideal for CAR-T development, ADC screening, and therapeutic antibody discovery.
Key Checkpoint Molecules
| Target Protein | Signal Type | Primary Interactor | Clinical Significance |
|---|---|---|---|
| PD-L1 | Inhibitory | PD-1 | T cell exhaustion, widely targeted in various cancers |
| LAG-3 | Inhibitory | MHC Class II, FGL1 | T cell exhaustion, synergy with PD-1 blockade |
| B7-H7 (HHLA2) | Co-inhibitory | CD28H | Alternative immune evasion pathway in PD-L1 negative tumors |
| FGL1 | Inhibitory | LAG-3 | Major immune inhibitory ligand for LAG-3 |
Tumor-Associated Antigens & Markers
Significance: Highly expressed in triple-negative breast cancer and urothelial cancer.
Significance: Ideal target for Hepatocellular Carcinoma (HCC).
Significance: Essential marker for Mesenchymal Stem Cells (MSC) and fibroblasts.
Significance: Defining marker for T helper cells, crucial for immune monitoring.
Immunotherapy Applications
CAR-T Development
Use high-affinity antigens for CAR construct screening, off-target toxicity assessment, and quality control of manufactured CAR-T cells.
ADC Screening
Evaluate Antibody-Drug Conjugate binding affinity and internalization kinetics using native-conformation recombinant targets.
Checkpoint Blockade
Validate inhibitory monoclonal antibodies through robust receptor-ligand binding and blocking assays.
Flow Cytometry
High-purity proteins suitable for fluorophore conjugation to analyze cell populations and receptor expression.
Advance Your Immuno-Oncology Pipeline
Partner with us for reliable, highly active checkpoint proteins and antigens that drive your drug discovery forward.